Gilead Sciences, Inc. vs Nuscale Power Corporation — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Gilead Sciences, Inc. is far larger — about 60.8× Nuscale Power Corporation's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Nuscale Power Corporation for 29 Days on average.
| GILD | SMR | |
|---|---|---|
Market Cap | $182.40B | $3.00B |
Volume | 4,469,821 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $155.80 | $53.43 |
52-Week Low | $117.18 | $7.32 |
Typical Hold Time | 111 Days | 29 Days |
Enterprise Value | $205.46B | $1.93B |
Dividend Yield | 2.23% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
NuScale Power (SMR) trades at $7.32, down 4.56% today, amid bearish technical signals and challenging fundamentals. The company reported significant losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Despite analyst consensus pointing to a $11.25 price target with 50% buy ratings, recent news highlights investor concerns including an ongoing legal investigation announced by Pomerantz Law Firm on October 1, 2026.
The stock faces substantial execution risks as it burns cash to commercialize small modular reactor technology. While nuclear energy presents long-term growth potential, SMR's path to profitability remains uncertain given current financial metrics and competitive pressures from established players like GE Vernova. The wide analyst target range ($6-$16) reflects divided sentiment on the company's prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →